Zamorano Mauricio, Castillo Rodrigo L, Beltran Jorge F, Herrera Lisandra, Farias Joaquín A, Antileo Christian, Aguilar-Gallardo Cristobal, Pessoa Adalberto, Calle Yolanda, Farias Jorge G
Department of Chemical Engineering, Universidad de La Frontera, Temuco, Chile.
Department of Internal Medicine, Universidad de Chile, Santiago, Chile.
Front Physiol. 2021 Sep 17;12:705256. doi: 10.3389/fphys.2021.705256. eCollection 2021.
Ischemia is a severe condition in which blood supply, including oxygen (O), to organs and tissues is interrupted and reduced. This is usually due to a clog or blockage in the arteries that feed the affected organ. Reinstatement of blood flow is essential to salvage ischemic tissues, restoring O, and nutrient supply. However, reperfusion itself may lead to major adverse consequences. Ischemia-reperfusion injury is often prompted by the local and systemic inflammatory reaction, as well as oxidative stress, and contributes to organ and tissue damage. In addition, the duration and consecutive ischemia-reperfusion cycles are related to the severity of the damage and could lead to chronic wounds. Clinical pathophysiological conditions associated with reperfusion events, including stroke, myocardial infarction, wounds, lung, renal, liver, and intestinal damage or failure, are concomitant in due process with a disability, morbidity, and mortality. Consequently, preventive or palliative therapies for this injury are in demand. Tissue engineering offers a promising toolset to tackle ischemia-reperfusion injuries. It devises tissue-mimetics by using the following: (1) the unique therapeutic features of stem cells, i.e., self-renewal, differentiability, anti-inflammatory, and immunosuppressants effects; (2) growth factors to drive cell growth, and development; (3) functional biomaterials, to provide defined microarchitecture for cell-cell interactions; (4) bioprocess design tools to emulate the macroscopic environment that interacts with tissues. This strategy allows the production of cell therapeutics capable of addressing ischemia-reperfusion injury (IRI). In addition, it allows the development of physiological-tissue-mimetics to study this condition or to assess the effect of drugs. Thus, it provides a sound platform for a better understanding of the reperfusion condition. This review article presents a synopsis and discusses tissue engineering applications available to treat various types of ischemia-reperfusions, ultimately aiming to highlight possible therapies and to bring closer the gap between preclinical and clinical settings.
缺血是一种严重病症,其中包括氧气(O)在内的器官和组织的血液供应被中断并减少。这通常是由于为受影响器官供血的动脉堵塞所致。恢复血流对于挽救缺血组织、恢复氧气和营养供应至关重要。然而,再灌注本身可能会导致重大不良后果。缺血再灌注损伤通常由局部和全身炎症反应以及氧化应激引发,并导致器官和组织损伤。此外,缺血持续时间和连续的缺血再灌注周期与损伤的严重程度相关,并可能导致慢性伤口。与再灌注事件相关的临床病理生理状况,包括中风、心肌梗死、伤口、肺、肾、肝和肠道损伤或衰竭,在发病过程中伴随着残疾、发病率和死亡率。因此,需要针对这种损伤的预防或姑息治疗方法。组织工程提供了一套有前景的工具来应对缺血再灌注损伤。它通过以下方式设计组织模拟物:(1)干细胞的独特治疗特性,即自我更新、分化能力、抗炎和免疫抑制作用;(2)驱动细胞生长和发育的生长因子;(3)功能性生物材料,为细胞间相互作用提供特定的微结构;(4)生物过程设计工具,以模拟与组织相互作用的宏观环境。这种策略能够生产出能够解决缺血再灌注损伤(IRI)的细胞治疗产品。此外,它还能开发生理组织模拟物来研究这种病症或评估药物的效果。因此,它为更好地理解再灌注状况提供了一个可靠的平台。这篇综述文章概述并讨论了可用于治疗各种类型缺血再灌注的组织工程应用,最终旨在突出可能的治疗方法,并缩小临床前和临床环境之间的差距。